Peter George joins Board of Ergomed as Non-Executive Director

He is currently Chief Executive of Clinigen

Peter George has joined the Board of Ergomed as Non-Executive Director.

George has more than 20 years’ experience in the pharmaceutical services industry and is currently Chief Executive of Clinigen, the global speciality pharmaceuticals and pharmaceutical services business. Prior to Clinigen, he was CEO at Penn Pharma, having led a £67m management company buyout in 2007.

Before this, George was Executive VP at Wolters Kluwer Health with responsibility for Europe and Asia Pacific regions. He has also held roles as Chief Operating Officer of Unilabs Clinical Trials International; Head of Clinical Pathology NHS and Director of PharmaPatents Global.

You may also like

Regulatory

Ergomed subsidiary PrimeVigilance enters US market and opens office in Boston, USA

US base gives PrimeVigilance the presence needed to support its current North American clients
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Vetter strengthens senior management team for growth

Three new managing directors to support global sustainable development
Manufacturing

IMed Consultancy helps Toby Orthopaedics navigate UK regulations

Regulatory consultancy ensures compliance and confidence for Miami-based company
Manufacturing

Ardena's Oss nanomedicine facility gains full GMP approval from the Dutch Healthcare Authority

The pharmaceutical manufacturing facility can produce advanced nanoparticle drug delivery systems, including lipid-based, polymeric and metal oxide nanoparticles
Regulatory

Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi

The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
Subscribe now